Shots:
- The company has developed Versavo as a biosimilar of Avastin, approved for the treatment of various cancer indications incl. metastatic colorectal cancer, advanced non-squamous NSCLC, recurrent glioblastoma, mRCC, advanced cervical cancer, ovarian cancer & metastatic breast cancer
- Based on the clinical evaluation, Versavo is expected to be approved and launched across the UK as a single-use vial in strengths 100 & 400mg
- Earlier in 2019, Dr. Reddy’s launched Versavo in India and has also launched the Avastin biosimilar in markets across Thailand, Ukraine, Nepal & Jamaica under the same brand name & in Colombia by Persivia
Ref: Dr. Reddy’s | Image: Dr. Reddy’s | Press Release
Related News:- Bio-Thera Solutions and SteinCares Collaborate for Marketing Biosimilars Across LATAM
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
